

TSE: 4502 TAK LISTED NYSE

Committed to Growth & Shareholder Returns

FY2024 Earnings Announcement

May 8th, 2025



Better Health, Brighter Future

Important Notice



For the purposes of this notice, "presentation" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("**Takeda**") regarding this presentation. This presentation (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this presentation. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This presentation is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this presentation, "Takeda" is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words "we", "us" and "our" are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners.

Forward-Looking Statements

This presentation and any materials distributed in connection with this presentation may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as "targets", "plans", "believes", "hopes", "continues", "expects", "aims", "intends", "ensures", "will", "may", "should", "could", "anticipates", "estimates", "projects", "forecasts", "outlook" or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the invest, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's ontained in this presentation or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an

Financial Information and Certain Non-IFRS Financial Measures

Takeda's financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS").

This presentation and materials distributed in connection with this presentation include certain financial measures not presented in accordance with IFRS, such as Core Revenue, Core Operating Profit, Core Net Profit, Core EPS, Constant Exchange Rate ("CER") change, Net Debt, EBITDA, Adjusted EBITDA, Free Cash Flow and Adjusted Free Cash Flow. Takeda's management evaluates results and makes operating and investment decisions using both IFRS and non-IFRS measures included in this presentation. These non-IFRS measures exclude certain income, cost and cash flow items which are included in, or are calculated differently from, the most closely comparable measures presented in accordance with IFRS. Takeda's non-IFRS measures are not prepared in accordance with IFRS and such non-IFRS measures should be considered a supplement to, and not a substitute for, measures prepared in accordance with IFRS (which we sometimes refer to as "reported" measures). Investors are encouraged to review the definitions and reconciliations of non-IFRS financial measures to their most directly comparable IFRS measures, which are in the financial appendix appearing at the end of this presentation.

Beginning in the first quarter of FY24, Takeda (i) changed its methodology for CER adjustments to results of subsidiaries in hyperinflation countries to present those results in a manner consistent with IAS 29, Financial Reporting in Hyperinflation Economies, and (ii) re-named Free Cash Flow as previously calculated as "Adjusted Free Cash Flow" (with "Free Cash Flow" now reported as Operating Cash Flow less Property, Plant and Equipment), and (iii) re-named Net Debt as previously calculated as "Adjusted Net Debt" (with "Net Debt" to be reported as the book value of bonds and loans less cash and cash equivalents). For more information about the changes, including how the new methodology would have impacted Takeda's FY23 results, as well as other important information about Takeda's non-IFRS measures, including the limitations on the usefulness thereof, refer to the Financial Appendix.

Peak Revenue Potential and PTRS Estimates

References in this presentation to peak revenue ranges are estimates that have not been adjusted for probability of technical and regulatory success (PTRS) and should not be considered a forecast or target. These peak revenue ranges represent Takeda's assessments of various possible future commercial scenarios that may or may not occur. References in this presentation to PTRS are to internal estimates of Takeda regarding the likelihood of obtaining regulatory approval for a particular product in a particular indication. These estimates reflect the subjective judgment of responsible Takeda personnel and have been approved by Takeda's Portfolio Review Committee for use in internal planning.

Exchange Rates

In this presentation, certain amounts presented in Japanese yen have been translated to US dollars solely for the convenience of the reader. Except where otherwise noted, these convenience translations have been made at an exchange rate of 1USD = 149.90, the Noon Buying Rate certified by the Federal Reserve Bank of New York on March 31, 2025. The rate and methodologies used for these convenience translations differ from the currency exchange rates and translation methodologies under IFRS used for the preparation of Takeda's consolidated financial statements. These translations should not be construed as a representation that the relevant Japanese yen amounts could be converted into U.S. dollars at this or any other rate.

Medical information

2

This presentation contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.





Opening Remarks & Business Highlights

Christophe Weber, President & CEO

Financial Highlights

Milano Furuta, Chief Financial Officer



Pipeline Update Andy Plump, President, R&D



Closing Remarks Christophe Weber, President & CEO

Q&A

Question & Answer Session

AGENDA

FY2024: Topline Growth & Margin Expansion Despite VYVANSE Generic Impact, with Accelerated Progress in our Late-Stage Innovative Pipeline



- Growth & Launch Products more than offset VYVANSE generic erosion to deliver Core Revenue growth
- Steady execution of Efficiency Program to deliver Core Operating Profit growth



or +270bps excluding VYVANSE⁴


+14.7% growth at CER

1. Please refer to appendix slide A-1 for definition of Core financial measures, and slide A-8 for reconciliation; 2. Please refer to disclaimer on Exchange Rates on slide 2; 3. Constant Exchange Rate. Please refer to appendix slide A-1 for definition

4 4. Calculated by excluding VYVANSE contribution from both FY23 and FY24 results.

Strong Momentum of Growth & Launch Products +14.7% at CER





Absolute values are FY2024 results presented on an IFRS (reported) basis; growth rates are year-on-year change at Constant Exchange Rate (CER) (please refer to appendix slide A-1 for definition).

- "% of Sales" reflects percentage of FY2024 Core Revenue
 - 1. Please refer to disclaimer on Exchange Rates on slide 2


Takeda's Global Manufacturing is Centered in U.S., Europe, Japan & Singapore *Takeda*

- Tariff exposure is determined by revenue contribution of imports, manufacturing location / country of origin, and transfer pricing policy.
- Based on current assumptions, Takeda believes our likely potential exposure to U.S. and China tariffs is limited.
 - ~50% of total Takeda revenue is from the U.S.; value of imports (primarily from Europe/Japan/Singapore) is ~8 to 10% of total U.S. revenue
 - ~4% of total Takeda revenue is from China; value of imports (from U.S.) is ~12 to 15% of total China revenue
- For imports that may be subject to potential tariff impacts, we are taking mitigation measures (e.g. inventory & supply chain management).

Global Manufacturing Network


22 internal global manufacturing sites, with **20** supplying the U.S., including **7** located in the U.S.

Strategic contract manufacturers also distributed across the U.S., Europe and Japan; ~70% of CMO spend is with U.S.-based CMOs



FY2025 a Pivotal Year as we Prepare for Late-Stage Pipeline Launches







Delivering rapid, consistent & sustained hematocrit control with potential for use at each step of the treatment landscape

> Peak revenue potential: \$1-2 billion

> > Ph3 data readout: March 2025 🗸

Oveporexton (TAK-861)

Narcolepsy Type 1



On track to be first-in-class orexin agonist with potential to transform NT1 treatment paradigm

> Peak revenue potential: \$2-3 billion

Expected Ph3 data readout: H1 FY2025

Zasocitinib (TAK-279) **Psoriasis**



Highly selective TYK2 inhibitor with potential to redefine what is possible with an oral therapy in psoriatic disease

> Peak revenue potential: \$3-6 billion¹

Expected Ph3 data readout: H2 FY2025

Please refer to the Important Notice at the start of this presentation for more information about peak revenue estimates

1. Peak sales total for psoriasis and psoriatic arthritis. Does not include potential upside from additional indications such as ulcerative colitis and Crohn's disease.

FY2025 Outlook: Final Year of Significant VYVANSE Generic Headwind; Preparing for New Product Launches from Late-Stage Pipeline



(BN YEN, except EPS)	REPORTED FY2025 FORECAST	CORE FY2025 FORECAST	CORE CHANGE AT CER FY2025 MANAGEMENT GUIDANCE
REVENUE	4,530.0	4,530.0	Broadly Flat
OPERATING PROFIT	475.0	1,140.0	Broadly Flat
EPS	145 yen	485 yen	Broadly Flat

ADJUSTED FREE CASH FLOW	750.0 – 850.0
ANNUAL DIVIDEND PER SHARE	200 yen

Key assumptions in FY2025 forecast:

- Takeda's forecast for FY2025 does not reflect the potential impact of tariffs being introduced on pharmaceutical products by the U.S. administration, nor the potential impact of tariffs introduced by other countries in response to U.S. tariffs. We continue to monitor the situation, including potential mitigation strategies, and will update our forecasts if and when a probable impact can be estimated.
- Forecast assumes global VYVANSE revenue of JPY 241.0B, a year-on-year decline of JPY 109.6B (-30% at CER).
- Forecast assumes 150 JPY/USD and 160 JPY/EUR. Please refer to appendix slide A-20 for more details on FX assumptions and sensitivity.



Opening Remarks & Business Highlights

Christophe Weber, President & CEO



Financial Highlights

Milano Furuta, Chief Financial Officer

Pipeline Update Andy Plump, President, R&D

Closing Remarks Christophe Weber, President & CEO

Question & Answer Session

AGENDA



FY2024 (APR-MAR) FINANCIAL RESULTS (SUMMARY)

(BN YEN, except EPS)	REPORTED							
	FY2024	FY2023	ACTUAL % CHANGE		FY2024	FY2023	ACTUAL % CHANGE	CER ² % CHANGE
REVENUE	4,581.6	4,263.8	+7.5%		4,579.8	4,263.8	+7.4%	+2.8%
OPERATING PROFIT	342.6	214.1	+60.0%		1,162.6	1,054.9	+10.2%	+4.9%
Margin	7.5%	5.0%	+2.5pp		25.4%	24.7%	+0.6pp	
NET PROFIT	107.9	144.1	-25.1%		775.6	756.8	+2.5%	-3.4%
EPS	68 yen	92 yen	-25.8%		491 yen	484 yen	+1.5%	-4.3%
OPERATING CASH FLOW	1,057.2	716.3	+47.6%					
ADJUSTED FREE CASH FLOW ³	769.0	283.4	+171.3%					

1. Please refer to appendix slide A-1 for definition of Core financial measures, and slides A-8 and A-10 for reconciliation.

10 2. Constant Exchange Rate. Please refer to appendix slide A-1 for definition

3. Please refer to appendix slide A-2 for definition and slide A-12 for reconciliation


FY2024 Results: Delivered Guidance for Revenue & Core O.P. Growth Takeda

MANAGEMENT GUIDANCE FOR FY2024 CORE GROWTH AT CER

	ORIGINAL GUIDANCE [MAY 2024]		LATEST GUIDANCE [JANUARY 2025]	FY2024 RESULTS
CORE REVENUE	Flat to slightly declining	>	Low-single digit % increase	+2.8%
CORE OPERATING PROFIT	Approx 10% decline		Low-single digit % increase	+4.9%
CORE EPS	Mid-10s% decline		Flat to slightly declining	-4.3%

- Core Revenue delivered latest guidance supported by product momentum including Growth & Launch Products
- Core Operating Profit at high-end of latest guidance due to continued OPEX efficiency
- Core EPS slightly below latest guidance due to higher than anticipated tax expenses

Efficiency Program Captured ~JPY 200.0B Annualized Savings to Date



Organizational
Agility3,000 positions to dateOptimizing org agility including spans & layersExited R&D site in San Diego: transferred dives

Structural changes impacting approximately

• Exited R&D site in San Diego; transferred divested manufacturing sites in Austria & Japan

Procurement Savings

 Initiatives to capture savings in categories such as contract manufacturing, R&D services, marketing support & resources, facilities, information technology, etc.

Data, Digital & Technology

- In-sourcing and enhancing DD&T capabilities with expansion of Innovation Capability Centers (ICCs)
- Leveraging data and AI across the entire value chain to create value, including in manufacturing, plasma collection, R&D, sales & marketing, G&A

Freeing up resources to:

- » Advance prioritized pipeline
- » Execute new product launches
- » Continue building DD&T capabilities
- » Offset inflation headwinds




FY2024 Revenue: Growth & Launch Products More Than Offset Loss of Exclusivity Impact Including VYVANSE



FY2024 REVENUE VS PRIOR YEAR

(BN JPY)




FY2024 Core Operating Profit: Growth & Launch Products More Than Offset LOE Impact, with OPEX Benefitting from Efficiency Program



FY2024 CORE OPERATING PROFIT VS PRIOR YEAR

(BN JPY)


14



FY2024 Reported Operating Profit: Increase Reflects Growth in Core Operating Profit and Lower Impairment Compared to Prior Year



FY2024 REPORTED OPERATING PROFIT VS PRIOR YEAR




15

FY2024 Adj. Free Cash Flow: Strong Result of JPY 769.0B Exceeding Forecast



FY2024 CASH FLOW

16



- 4. "Short-term debt" refers to JPY denominated Commercial Paper and USD denominated Bilateral Loan.
- 5. "Net Change in Long-term Debt": (Decrease) USD 1.5B SAIIDAC Bond Tender prepayment in July 2024, JPY 500.0B Hybrid bond Redemption in October 2024, and JPY 313.5B + USD 1.5B Syndicated Loan early repayments in March 2025


(Increase) JPY 460.0B Hybrid Bond Issuance in June 2024, USD 3.0B Bond Issuance in July 2024, and JPY 40.0B Hybrid Loan borrowing in October 2024

6. "Other" includes items such as Level 1 debt investment in US Treasuries, FX impact on cash, lease obligations and cash proceeds from re-setting of certain derivatives

Note: Slide includes non-IFRS metrics. Please refer to appendix for definitions and reconciliations. 1. Please refer to disclaimer on Exchange Rates on slide 2. Total liquidity includes Level 1 debt investment in US Treasuries (JPY 79.3B). 2. "Divestments / Other" includes proceeds from sale of assets (securities/real estate etc.) net of certain investments. 3. "Pass-through cash adjustment" refers to changes in cash balance that is temporarily held by Takeda on behalf of third parties related to vaccine operations and the trade receivables sales program. This Adjustment ensures that Free Cash Flow is not impacted by any change in Pass-through cash during the current reporting period.



FY2024 CHANGE IN ADJUSTED NET DEBT




Note: Slide includes non-IFRS metrics. Please refer to appendix for definitions and reconciliations.

1. "Divestments / Other" includes proceeds from sale of assets (securities/real estate etc.) net of certain investments 2. "Pass-through cash adjustment" refers to changes in cash balance that is temporarily held by Takeda on behalf of third parties related to vaccine operations and the trade receivables sales program. This Adjustment ensures that Free Cash Flow is not impacted by any change in

Pass-through cash during the current reporting period. 3. Includes cash and non-cash adjustments to debt book-value, lease obligations, certain investments and re-setting of certain derivatives. Non-cash adjustments include changes due to debt amortization and FX impact from converting non-JPY debt into JPY. 4. Excludes pass-through cash balance of JPY 105.8B; Includes Level 1 debt investment in US Treasuries of JPY 79.3B 17

Prepaid Syndicated Loans in Q4 with Cash On-hand & Short-term Funding; Short-term Funding to be Re-financed in FY2025



MATURITY LADDER AS OF MARCH 31, 2025

Prepaid Syndicated Loans (JPY 313.5B and USD 1,500M) in Q4 with Cash On-hand, Commercial Paper JPY 270.0B and Short-term Loan USD 500M

100% Debt at Fixed rate (~2% Weighted Average); Average Debt Maturity ~9 years

1. In October 2024, Takeda paid for early redemption of Hybrid Bonds (Issued in June 2019, maturity date of June 2079) on their first call date using proceeds from Hybrid Bonds Issuance (Q1, JPY 460B) and Hybrid Loans Issuance (Q3, JPY 40B)

Non-JPY debt principal calculated as at end of March 2025 FX Rates (149.01 JPY/USD and 161.33 JPY/EUR). This reflects the actual conversion rate used for reporting purposes.

18

^{2.} FY 84 Hybrid Debt (JPY 500B) comprises JPY 460B Hybrid Bonds (Issued in June 2024, maturity date of June 2084) and Hybrid Loans (JPY 40B Issued in October 2024, maturity date of October 2084).

FY2025 Outlook: Final Year of Significant VYVANSE Generic Headwind; Preparing for New Product Launches from Late-Stage Pipeline



(BN YEN, except EPS)	EN, except EPS) REPORTED		co	DRE	CORE CHANGE AT CER
	FY2025 FORECAST	VS. PRIOR YEAR	FY2025 FORECAST	VS. PRIOR YEAR	FY2025 MANAGEMENT GUIDANCE
REVENUE	4,530.0	-1.1%	4,530.0	-1.1%	Broadly Flat
OPERATING PROFIT	475.0	+38.7%	1,140.0	-1.9%	Broadly Flat
EPS	145 yen	+111.8%	485 yen	-1.2%	Broadly Flat

ADJUSTED FREE CASH FLOW	750.0 – 850.0
ANNUAL DIVIDEND PER SHARE	200 yen


Key assumptions in FY2025 forecast:

- Takeda's forecast for FY2025 does not reflect the potential impact of tariffs being introduced on pharmaceutical products by the U.S. administration, nor the potential impact of tariffs introduced by other countries in response to U.S. tariffs. We continue to monitor the situation, including potential mitigation strategies, and will update our forecasts if and when a probable impact can be estimated.
- Forecast assumes global VYVANSE revenue of JPY 241.0B, a year-on-year decline of JPY 109.6B (-30% at CER).
- Forecast assumes 150 JPY/USD and 160 JPY/EUR. Please refer to appendix slide A-20 for more details on FX assumptions and sensitivity.

Core Revenue Expected to be Broadly Flat at CER, with Growth & Launch Products Momentum Offsetting Carry-over of VYVANSE Generic Impact



FY2025 REVENUE FORECAST



Graphs are illustrative


20

Note: Slide includes non-IFRS metrics. Please refer to appendix for definitions and reconciliations. In FY2025, Reported Revenue and Core Revenue are expected to be equivalent, with no Core adjustment.

Core O.P. Expected to be Broadly Flat at CER, with Efficiency Program Savings, & Investments in R&D, DD&T, and Launch Preparation for Late-stage Pipeline



FY2025 CORE OPERATING PROFIT FORECAST



Graphs are illustrative.

21

Note: Slide includes non-IFRS metrics. Please refer to appendix for definitions and reconciliations


 In March 2025, Takeda entered into a development funding agreement with Blackstone Life Sciences ("BXLS") for mezagitamab. Under this agreement, Takeda will receive up to a total of USD 300 million to co-fund Phase 3 trials of mezagitamab in ITP and IgAN from FY2025 through FY2028. Takeda will recognize the funding as a reduction of R&D expenses as incurred. BXLS is eligible to receive regulatory approval milestones of up to USD 240 million and cumulative sales milestones of up to USD 300 million if all related milestones are achieved. Additionally, upon commercialization, BXLS will be entitled to receive royalties on U.S. sales.

Reported Operating Profit Forecast Reflects Lower Restructuring Expenses and Conclusion of VYVANSE Amortization in January 2026



FY2025 REPORTED OPERATING PROFIT FORECAST

(BN JPY)




Note: Slide includes non-IFRS metrics. Please refer to appendix for definitions and reconciliations

Committed to Growth & Shareholder Returns



Guided by our vision to discover and deliver life-transforming treatments, and supported by our balance sheet (maintaining solid investment grade credit ratings; targeting 2x adjusted net debt / adjusted EBITDA), we will allocate capital to deliver sustainable value to patients and attractive returns to our shareholders.



Strategic investment in:

- Internal & external opportunities to enhance the pipeline
- New product launches
- Plasma-Derived Therapies

- Progressive dividend policy of increasing or maintaining the dividend each year
 - » Proposed increase to 200 yen in FY2025
- Share buybacks when appropriate



Opening Remarks & Business Highlights

Christophe Weber, President & CEO

Financial Highlights Milano Furuta, Chief Financial Officer



Pipeline Update Andy Plump, President, R&D


Closing Remarks Christophe Weber, President & CEO

Question & Answer Session

AGENDA

Key FY24 Pipeline Achievements: Advancing Late-Stage Pipeline






IgAN: immunoglobulin A nephropathy

MDS: myelodysplastic syndrome MF: myelofibrosis

vWD: von Willebrand disease

FY25 is a Pivotal Year with Three Anticipated Phase 3 Data Readouts






26

ASCO Plenary Session: Rusfertide Phase 3 VERIFY Study Met Primary and All Four Key Secondary Endpoints in Phlebotomy-Dependent Patients with Polycythemia Vera (PV)





* Clinical responders: were not phlebotomy eligible during wks 20-32 AND did not receive a phlebotomy during wks 20-32


**Ongoing therapy could include therapeutic phlebotomy and/or cytoreductive therapy.

Next steps: Phase 3 data at ASCO 2025 plenary session → Safety/durability of response at week 52 → Filing in U.S. in H2 FY2025

27

Data Driven Decisions FY24: Continuing Focus on Most Promising Programs






28 4. Positive Phase 2b data; agreement with Neurocrine amended; Takeda re-acquired Japan rights.

All timelines are approximate estimates as of May 8th, 2025, are subject to change and are subject to clinical and regulatory success. Table is not comprehensive. Only major regions (U.S., EU, Japan, China). For full glossary of abbreviations please refer to appendix.

Accelerating the Development of Life Transforming Medicines which have the Potential to Generate Significant Value





29 All timelines are approximate estimates as of May 8th, 2025, are subject to change and are subject to clinical and regulatory success. Table only shows selected R&D milestones and is not comprehensive. For full glossary of abbreviations please refer to appendix.



Opening Remarks & Business Highlights

Christophe Weber, President & CEO

Financial Highlights

Milano Furuta, Chief Financial Officer

Pipeline Update Andy Plump, President, R&D




Closing Remarks Christophe Weber, President & CEO

Question & Answer Session

AGENDA

Foundations in Place to Support New Chapter of Growth for Takeda





- Limited expected generic exposure in portfolio until early 2030s¹
- Three new molecular entities with Phase 3 data readouts expected by end of CY2025

 Investing in R&D and pursuing asset-specific business development to further enhance long-term corporate value

Targeting Core Operating Profit margin improvement to reach low-to-mid 30s%

31 1. Major products expected to face generic/biosimilar competition between FY2024-2029 represent ~10% of FY2024 revenue: Gattex U.S. (Patent expired; timing of potential generic entry unknown), Trintellix U.S. (Patent expires Dec '26), Iclusig U.S. (Patent expires Jan '27), Vectibix JP (generic launch anticipated FY26), Vyvanse EU (Patent expires FY24-29 depending on country), Livtencity U.S. (regulatory protection expires Nov '28), Ninlaro U.S. (Patent expires Nov '29)

Better Health for People, Brighter Future for the World

Our vision is to discover and deliver life-transforming treatments, guided by our commitment to:

PATIENT

- Responsibly translate science into highly innovative, life-changing medicines and vaccines
- Accelerate access to improve lives worldwide

PEOPLE

 Create an exceptional people experience

PLANET

Protect our planet

... AND BY UNLEASHING THE POWER OF DATA AND DIGITAL

• We strive to transform Takeda into the most trusted, science-driven, digital biopharmaceutical company

We are guided by our values of Takeda-ism which incorporate Integrity, Fairness, Honesty, and Perseverance, with Integrity at the core. They are brought to life through actions based on Patient-Trust-Reputation-Business, in that order.



Q&A SESSION



CHRISTOPHE WEBER Representative Director; President & CEO



ANDY PLUMP Director; President, Research & Development



MILANO FURUTA Director; Chief Financial Officer



JULIE KIM President, US Business Unit



GILES PLATFORD President, Plasma-Derived Therapies Business Unit



TERESA BITETTI President, Global Oncology Business Unit



APPENDIX




GASTROENTEROLOGY (GI)

ENTYVIO Growth Momentum Building with Expansion of ENTYVIO PEN



GI PORTFOLIO



Entyvio[®] FY2024 Revenue JPY 914.1B (+8.5% growth)

- ENTYVIO maintains share leadership even as IBD treatment options increase
- In the U.S., ENTYVIO remains the #1 brand in IBD (UC and Crohn's combined) with total IBD patient share remaining stable over the last year.¹ Also, ENTYVIO maintains patient share as the lead 1L biologic in UC bio-naïve new starts despite new entrants
- With the Pen now available for UC and Crohn's in the U.S., we are unlocking the full potential of the IBD market with increased awareness and positive experiences among patients and HCPs
- In Europe, ENTYVIO continues to outperform the overall IBD advanced therapy market, fueled by SC penetration, strong patient growth and maintaining steady share with fewer pricing headwinds compared to prior year
- Investment in studies to support targets of disease clearance and endoscopic healing, plus studies investigating the potential role of combination therapies to break efficacy ceiling with vedolizumab as backbone
- No change to assumption of biosimilar entry timing. Any biosimilar that seeks to launch prior to 2032 would need to address potential infringement and / or the validity of all relevant patents

(budesonide oral suspension) 2ma FY2024 Revenue JPY 5.5B (+2,500% growth)

- Patient demand for EOHILIA continues to grow month over month since launch in February 2024
- Growth supported by over 80% unaided HCP awareness and initial positive patient experience; U.S. team remains focused on HCP and patient engagement and education
- EOHILIA is the only FDA-approved treatment with a strong recommendation as a first-line treatment option for Eosinophilic Esophagitis, based on the American College of Gastroenterology guidelines

Absolute values are presented on an IFRS (reported) basis; Year-on-year changes are at CER (please refer to appendix slide A-1 for definition).

1. Source: US Patient Share – IQVIA - March 2025


RARE DISEASES

TAN

Sustained TAKHZYRO Momentum with Double-Digit Growth and >6,000 patients treated; LIVTENCITY Strong Market Penetration in the U.S. & Rapid Geo Expansion



RARE DISEASES PORTFOLIO FY2024 REVENUE



36 Absolute values are presented on an IFRS (reported) basis; Year-on-year changes are at CER (please refer to appendix slide A-1 for definition)

FY2024 Revenue JPY 223.2B (+18.9% growth)

- 7 years in the market, TAKHZYRO continues to be the #1 prescribed modern long-term prophylaxis with strong performance and >6,000 patients on treatment driven by:
 - Strong global demand (commercial presence now in >55 countries with strong patient growth) supported by compelling real-world evidence for >2.5 years on therapy with demonstrated improved Quality of Life (potential for zero attacks)
 - o Strong patient persistency and rising prophylactic market growth
- TAKHZYRO is the first and only Long-Term Prophylactic HAE treatment available for patients 2 years of age and up. Worldwide pediatric launches continue with positive progress in the U.S., European and emerging markets

(maribavir)^{tablets}

FY2024 Revenue JPY 33.0B (+64.5% growth)

- LIVTENCITY continues to show strong U.S performance driven by increased breadth and depth of activated centers, new and repeat prescribers, and positive market access trends leading to growth in new patient starts
- Real world utilization has demonstrated highly individualized treatment with partially longer treatment duration and a potential broader patient base
- Rapid geo expansion: Available in >30 countries worldwide; recent launch in Japan and NRDL coverage in China

ADZYNMA ADAMTS13, recombinant-krhn FY2024 Revenue JPY 7.1B (+1,516% growth)

- Strong launch trajectory: Launched for cTTP in the U.S., Japan, Germany and Austria, and approval granted in Brazil in December 2024. Further launches planned for EU and emerging markets
- Momentum driven by high HCP interest for an ultra-rare patient population with a tremendous unmet need
- Commercial launch and uptake in cTTP is exceeding our initial ambition, with patients continuing to transition quickly from historical treatments to ADZYNMA

HCP: Healthcare professional


PLASMA-DERIVED THERAPIES

PDT Portfolio Continues to Deliver Outstanding Growth Fueled By Sales of Immunoglobulin Products



PDT PORTFOLIO

 $\langle \rangle$



Immunoglobulin

FY24 Revenue JPY 757.8B (+11.5% growth)

- Strong demand globally, especially in the U.S., coupled with steady and growing supply
- Expansion of SCIG portfolio; double-digit % revenue growth
- Continued investment in innovation and differentiation of IG portfolio

MMAGARDLIQUID

Dvia mal Immunoglobulin (10%) nt Human Hyaluronidase

Albumin

FY24 Revenue JPY 141.4B (+1.1% growth)

- Strong demand globally, despite headwinds impacting demand and supply in China
- FY2024 growth impacted by planned necessary upgrades to manufacturing operations
- Anticipate return to a growth trajectory of high single digit % in FY2025

(Human Albumin)

CONTINUING TO INVEST IN PLASMA DONATION AND CAPACITY EXPANSION

- Plasma donation volume continues to grow with an expanding network, reaching 275 centers after opening 15 in FY2024. FY2025 growth will focus on ramping up new centers and network transformation
- Initiated personalized nomogram deployment in FY2024 to safely boost plasma donation volumes; expect full U.S. rollout by end of FY2025
- Significant investment in data and digital helps attract and retain donors through the delivery of an exceptional, personalized and differentiated donor experience
- Targeted investments across manufacturing network continue to increase yield, expand capacity and create efficiencies, leveraging data, digital & technology capabilities

37 Absolute values are presented on an IFRS (reported) basis; Year-on-year changes are at CER (please refer to appendix slide A-1 for definition).


ONCOLOGY

ည်ိ

Steady Growth Across Key Brands in Oncology Marketed Portfolio



ONCOLOGY PORTFOLIO FY2024 REVENUE



Absolute values are presented on an IFRS (reported) basis; Year-on-year changes are at CER (please refer to appendix slide A-1 for definition).

0 **Fruzaqla**[®] (fruguintinib) capsules

FY2024 Revenue JPY 48.0B (+351% growth)

- Approved or launched in more than 20 countries in FY24; growth driven by strong uptake in the U.S.
- Reimbursement received in the U.S. and Japan, among other countries; rapid advancement in reimbursement and pricing negotiations continuing
- Key drivers include the need for new treatment options in mCRC and ongoing positive feedback from oncologists

FY2024 Revenue JPY 129.0B (+14.8% growth) 15 brentuximab vedotin

- Increased use in 1L Hodgkin lymphoma is primary driver of growth
- In April 2025, the CHMP adopted a positive opinion for ADCETRIS for the treatment of adult patients with newly diagnosed stage IIb/III/IV Hodgkin lymphoma in combination with ECADD
- BrECADD treatment combination now included in HL guidelines from NCCN (category 1), GHSG (German Hodgkin Study Group) and other international guidelines



DCetr

FY2024 Revenue JPY 70.7B (+23.0% growth)


Continued growth due to U.S. label expansion for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy

NCCN: National Comprehensive Cancer Network. BrECADD: ADCETRIS in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone. For full glossary of abbreviations please refer to appendix.

- 1. FRUZAQLA is in-licensed from HUTCHMED Limited; Takeda has the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside of mainland China. Hong Kong and Macau
- 2. Takeda has commercialization rights for ICLUSIG in the U.S., Australia and Canada. Outside of the U.S., Australia and Canda, ICLUSIG is marketed in over 60 markets by four
- 3. ADCETRIS is in-licensed from Pfizer Inc. (Seagen acquired by Pfizer in December 2023); Takeda has global co-development and marketing rights outside of the U.S. and Canada.

QDENGA Demand Continues to Exceed Expectations







- Strong global demand: now available in 29 countries, including 19 European countries with travel recommendations to support use of QDENGA to help protect travelers to dengue endemic areas
- Increasing breadth and depth in these markets and further geo expansion drive additional growth, e.g. launch in Malaysia in June, Israel in July, and Vietnam & Switzerland in September 2024
- Productive discussions ongoing with governments in endemic markets towards inclusion in National Immunization Programs (NIP)
 - Available through NIP/regional programs in 2 countries: Brazil (approved Mar 2023, available Dec 2023) and Argentina (approved Apr 2023, available Aug 2024)
- Acknowledgement by important global organizations drives awareness and access for QDENGA
 - World Health Organization (WHO) has added QDENGA to its List of Prequalified Vaccines
 - Available through PAHO's Revolving Fund in 2 countries: Honduras (Oct 2024) and Peru (Oct 2024)
 - The Gavi Board recently approved support for a dengue vaccine program which is a major milestone towards broadening access
- Pursuing private and public partnerships with governments, institutional businesses, NGOs and manufacturers to expand access
- Approximately 9 million doses manufactured in FY2024, plan to reach 15.5 million doses in FY2025; on track towards reaching 100 million doses by FY2030

Absolute values are presented on an IFRS (reported) basis;
 Year-on-year changes are at CER (please refer to appendix slide A-1 for definition).

PAHO: Pan American Health Organization Gavi: Global Alliance for Vaccines and Immunization


NEUROSCIENCE

(A)

VYVANSE U.S. Loss of Exclusivity Impact from August 2023










FY2024 Revenue JPY 350.6B (-21.6% change)



- U.S. revenue declined -29.2% at CER in FY2024, impacted by Loss of Exclusivity that occurred August 2023
- Outside the U.S., major markets where VYVANSE/ELVANSE has experienced Loss of Exclusivity to date include Canada (Jun 2024), Brazil (Jul 2024), and Germany (Aug 2024).

Trintellix vortioxetine

FY2024 Revenue JPY 125.7B (+14.2% growth)


- In the U.S., growth of +13.6% at CER benefitting from lower gross-to-nets compared to prior year primarily due to shifts in payer mix (Medicaid prior period true-ups, and lower 340b utilization)
- In Japan, demonstrating continued strong momentum with +19.6% growth in FY2024

Absolute values are presented on an IFRS (reported) basis;1.Year-on-year changes are at CER (please refer to appendix slide A-1 for definition).2.

TRINTELLIX is in-licensed from Lundbeck; Takeda has commercialization rights in the U.S. and co-marketing rights in Japan.
 Source: IQVIA

Maximizing Potential of Marketed Portfolio Through LCM Expansions





2. HyHub: Advanced vial access for a sterile, single-use medical device that significantly simplifies the preparation and delivery of fSCIG from vials

3. QDENGA approved in Vietnam (May 2024), Israel (May 2024), Switzerland (July 2024)

41 All timelines are approximate estimates as of May 8th, 2025, are subject to change and are subject to clinical and regulatory success. Table only shows selected R&D milestones and is not comprehensive. For full glossary of abbreviations please refer to appendix.

FY24 Report Card for NME Approvals and Indication Expansions



	ENTYVIO SC	Crohn's disease	U.S. approval	 Image: A start of the start of
	QDENGA	Dengue vaccine	Additional endemic countries ¹	\checkmark
	POTENTIAL BULATORY PROVALS LIVTENCITY	сТТР	EU approval	\checkmark
KEY POTENTIAL	FRUZAQLA	mCRC	EU approval	~
			JP approval	
AFFILOVALS	LIVTENCITY	Refractory post-transplant CMV infection/disease	JP approval	\checkmark
	HYQVIA	PID, SID	JP approval	\checkmark
	maralixibat	Alagille syndrome (ALGS)	JP approval	\checkmark
	IIIdi diixiyat	Progressive familial intrahepatic cholestasis (PFIC)	JP approval	\checkmark
		Dravat Sundrama	Phase 3 Readout	×
KEY PHASE 3	soticlestat	Dravet Syndrome		
READOUTS		Lennox-Gastaut Syndrome	Phase 3 Readout	×
	rusfertide	Polycythemia Vera	Phase 3 Readout	



1. QDENGA approved in Vietnam (May 2024), Israel (May 2024), Switzerland (July 2024)

A "readout(s)" for a clinical trial occurs when Takeda has (1) received the relevant clinical data, (2) completed any necessary analysis and review of such clinical data, and (3) in instances where it is required or otherwise common convention or practice, consulted with applicable regulatory authorities regarding such clinical data.

42 All timelines are approximate estimates as of May 8th, 2025, are subject to change and are subject to clinical and regulatory success. Table only shows selected R&D milestones and is not comprehensive. For full glossary of abbreviations please refer to appendix.

Preparing for an Exciting FY25: Potential Key Phase 3 NME Readouts and Indication Expansions



X Milestone not achieved


	oveporexton	Narcolepsy type 1	Phase 3 readout
KEY PIVOTAL READOUTS	zasocitinib	Psoriasis	Phase 3 readout
	mirvetuximab	Platinum resistant ovarian cancer	Pivotal readout ¹
	ADCETRIS	Frontline Hodgkin lymphoma (BrECADD regimen)	EU approval
KEY POTENTIAL	VONVENDI	Pediatric von Willebrand disease (on-demand/surgery)	U.S. approval
APPROVALS TAK-880		Low IgA IgG primary immunodeficiency	U.S. approval EU approval
			Milestone achieved

A "readout(s)" for a clinical trial occurs when Takeda has (1) received the relevant clinical data, (2) completed any necessary analysis and review of such clinical data, and (3) in instances where it is required or otherwise common convention or practice, consulted with applicable regulatory authorities regarding such clinical data. 1. Phase 1/2 Pivotal trial which may allow for filing in Japan.

43 All timelines are approximate estimates as of May 8th, 2025, are subject to change and are subject to clinical and regulatory success. Table only shows selected R&D milestones and is not comprehensive. For full glossary of abbreviations please refer to appendix.

Consolidated Development Pipeline by Phase






44 All timelines are approximate estimates as of May 8th, 2025, are subject to change and are subject to clinical and regulatory success. Table is not comprehensive. For full glossary of abbreviations please refer to appendix.

Consolidated Development Pipeline by Phase





conditions including regulatory approval.

45

All timelines are approximate estimates as of May 8th, 2025, are subject to change and are subject to clinical and regulatory success. Table is not comprehensive. For full glossary of abbreviations please refer to appendix.

Zasocitinib (TAK-279): Best-in-class potential due to high selectivity, once daily oral administration



Milestone achieved

Latitude	PHASE 2b START	PHASE 2b READOUT	PHASE 3	FILING
		Ph2b March 2023	Vh3 Start FY2023	Target FY2026
Psoriasis			H2H vs. deucravacitinib Start FY2025	
Psoriatic Arthritis		Ph2b September 2023	Ph3 Start FY2024	Target FY28/29
Crohn's Disease	Ph2b March 2024	Target FY2026		
Ulcerative Colitis	Ph2b June 2024	Target FY2026		
Vitiligo	Ph2 FY2025			

Zasocitinib is a highly selective (TYK2 over JAKs ~1.3 M times) once daily pill


- TYK2, IL-23, IL-12 therapies active in many autoimmune diseases
- Genetic data: Loss of TYK2 function reduces risk in PsO, PsA, Crohn's, UC, others
- Preclinical models support use

Strong clinical validation for mechanism across multiple autoimmune conditions:

Promising for immunological disorders including IBD

Continuing Evidence Generation and Indication Expansion





All timelines are approximate estimates as of May 8th, 2025, are subject to change and are subject to clinical and regulatory success. Table is not comprehensive. For full glossary of abbreviations please refer to appendix.

Diverse and Experienced Takeda Executive Team





CEO

CHRISTOPHE WEBER¹ Representative Director; President & CEO



Business Units

JULIE KIM President, US Business Unit





ANDY PLUMP Director; President, Research & Development



Business Functions

GABRIELE RICCI Chief Data & Technology Officer





LAUREN DUPREY Chief Human Resources Officer



RAMONA SEQUEIRA² President, Global Portfolio Division



ASUKA MIYABASHIRA President, Japan Pharma Business Unit



GILES PLATFORD President, Plasma-Derived Therapies Business Unit

48

3.



TERESA BITETTI President, Global Oncology Business Unit

THOMAS WOZNIEWSKI Global Manufacturing & Supply Officer





MARCELLO AGOSTI Global Business Development Officer



AKIKO AMAKAWA Corporate Strategy Officer, CEO Chief of Staff



MILANO FURUTA

Officer

Director; Chief Financial

MWANA LUGOGO Chief Ethics & Compliance Officer



TAKAKO OHYABU Chief Global Corporate Affairs & Sustainability Officer



YOSHIHIRO NAKAGAWA³ Global General Counsel Until June 30th, 2025



NATALIE FURNEY Global General Counsel *From July* 1st, 2025

_____i

1. Christophe Weber has announced his intention to retire in June 2026, to be succeeded by Julie Kim as CEO

2. Ramona Sequeira has announced her intention to retire in summer 2025

Yoshihiro Nakagawa will retire at the end of June 2025, and will remain a special advisor through July 2026

Glossary of Abbreviations

Regional Abbreviations:

CN: China; EU: Europe; JP: Japan; U.S.: United States of America

AA	anemia-associated
AATD	α1-antitrypsin deficiency
AATD LD	α 1-antitrypsin deficiency associated liver disease
ADAMTS13	a disintegrin-like and metalloproteinase with a thrombospondin type 1 motifs 13
ADC	antibody-drug conjugate
AE	adverse event
ALGS	Alagille syndrome
ASCO	American Society of Clinical Oncology
ASH	American Society of Hematology
ASN	American Society of Nephrology
AVA	Advanced Vial Access
BID	bis in die, twice a day
BTD	breakthrough therapy designation
CAR NK	chimeric antigen receptor natural killer cell
СНМР	Committee for Medicinal Products for Human Use
CIDP	chronic inflammatory demyelinating polyradiculoneuropathy
CIDP CML	chronic inflammatory demyelinating polyradiculoneuropathy chronic myeloid leukemia
-	
CML	chronic myeloid leukemia
CML CMV	chronic myeloid leukemia cytomegalovirus
CML CMV CP-CML	chronic myeloid leukemia cytomegalovirus chronic-phase chronic myeloid leukemia
CML CMV CP-CML CRC	chronic myeloid leukemia cytomegalovirus chronic-phase chronic myeloid leukemia colorectal cancer
CML CMV CP-CML CRC CRPC	chronic myeloid leukemia cytomegalovirus chronic-phase chronic myeloid leukemia colorectal cancer castrate-resistant prostate cancer
CML CMV CP-CML CRC CRPC cTTP	chronic myeloid leukemia cytomegalovirus chronic-phase chronic myeloid leukemia colorectal cancer castrate-resistant prostate cancer congenital thrombotic thrombocytopenic purpura
CML CMV CP-CML CRC CRPC cTTP DOAC	chronic myeloid leukemia cytomegalovirus chronic-phase chronic myeloid leukemia colorectal cancer castrate-resistant prostate cancer congenital thrombotic thrombocytopenic purpura direct oral anti-coagulation
CML CMV CP-CML CRC CRPC cTTP DOAC DS	chronic myeloid leukemia cytomegalovirus chronic-phase chronic myeloid leukemia colorectal cancer castrate-resistant prostate cancer congenital thrombotic thrombocytopenic purpura direct oral anti-coagulation Dravet syndrome
CML CMV CP-CML CRC CRPC cTTP DOAC DS EGFR	chronic myeloid leukemia cytomegalovirus chronic-phase chronic myeloid leukemia colorectal cancer castrate-resistant prostate cancer congenital thrombotic thrombocytopenic purpura direct oral anti-coagulation Dravet syndrome epidermal growth factor receptor
CML CMV CP-CML CRC CRPC cTTP DOAC DS EGFR EMA	chronic myeloid leukemia cytomegalovirus chronic-phase chronic myeloid leukemia colorectal cancer castrate-resistant prostate cancer congenital thrombotic thrombocytopenic purpura direct oral anti-coagulation Dravet syndrome epidermal growth factor receptor European Medicines Agency
CML CMV CP-CML CRC CRPC cTTP DOAC DS EGFR EMA FDA	chronic myeloid leukemia cytomegalovirus chronic-phase chronic myeloid leukemia colorectal cancer castrate-resistant prostate cancer congenital thrombotic thrombocytopenic purpura direct oral anti-coagulation Dravet syndrome epidermal growth factor receptor European Medicines Agency U.S. Food & Drug Administration

GI	gastrointestinal
GvHD	graft versus host disease
H2H	head-to-head
HAE	hereditary angioedema
НСР	healthcare professional
HemA	hemophilia A
HL	Hodgkin lymphoma
IBD	inflammatory bowel disease
IgA	immunoglobulin A
IgAN	immunoglobulin A nephropathy
lgG	immunoglobulin G
IH	idiopathic hypersomnia
IND	investigational new drug
INN	international non-proprietary name
ISTH	International Society on Thrombosis and Haemostasis
ITP	immune thrombocytopenia
iTTP	immune thrombotic thrombocytopenic purpura
IV	intravenous
JAK	Janus kinase
LCM	lifecycle management
LGS	Lennox-Gastaut syndrome
mCRC	metastatic colorectal cancer
MDD	major depressive disorder
MDS	myelodysplastic syndrome
MF	myelofibrosis
MFSAF	Myelofibrosis Symptom Assessment Form
MMN	multifocal motor neuropathy
MSA	multiple system atrophy
NDA	new drug application
NK	natural killer
NME	new molecular entity

NMPA	(China's) National Medical Products Administration
NT1 or 2	narcolepsy type 1 or 2
OX2R	orexin 2 receptor
PDT	plasma derived therapies
PFIC	progressive familial intrahepatic cholestasis
Ph+ ALL	Philadelphia chromosome-positive acute lymphoblastic leukemia
PID	primary immunodeficiency
РК	pharmacokinetics
PMDA	Japan's Pharmaceuticals and Medical Devices Agency
РОС	proof of concept
PRIME	Priority medicines scheme by EMA
PROC	platinum-resistant ovarian cancer
PROMIS	Patient-Reported Outcomes Measurement Information System
PsO	psoriasis
PSOC	platinum-sensitive ovarian cancer
PTRS	probability of technical and regultory success
PV	polycythemia vera
QD	quaque die, every day
QOL	quality of life
RTU	ready to use
SAE	serious adverse event
SC	subcutaneous formulation
SID	secondary immunodeficiency
soc	standard of care
ткі	tyrosine kinase inhibitor
ТҮК2	tyrosine kinase 2
UC	ulcerative colitis
vWD	von Willebrand disease
wk(s)	week(s)
ww	worldwide



FINANCIAL APPENDIX



Definition of Non-IFRS Measures	
Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations	A-1
Reconciliations and Other Financial Information	
FY2024 Reported Results with CER % Change	A-4
FY2024 Q4 (Jan-Mar) Reported Results with CER % Change	A-5
FY2024 Core Results with CER % Change	A-6
FY2024 Q4 (Jan-Mar) Core Results with CER % Change	A-7
FY2024 Reconciliation from Reported to Core	A-8
FY2024 Q4 (Jan-Mar) Reconciliation from Reported to Core	A-9
FY2023 Reconciliation from Reported to Core	A-10
FY2023 Q4 (Jan-Mar) Reconciliation from Reported to Core	A-11
FY2024 Adjusted Free Cash Flow	A-12
FY2024 Adjusted Net Debt to Adjusted EBITDA	A-13
FY2023 Adjusted Net Debt to Adjusted EBITDA	A-14
FY2024 Net Profit to Adjusted EBITDA Bridge	A-15
FY2024 CAPEX, Depreciation and Amortization and Impairment Losses	A-16
FY2024 Results vs. Forecast (Jan. 2025)	A-17
FY2025 Full Year Detailed Forecast	A-18
FY2025 Full Year Reconciliation from Reported Operating Profit to Core Operating Profit Forecast	A-19
FY2025 Full Year FX Rates Assumptions and Currency Sensitivity vs. Forecast	A-20

Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations

Takeda

Core Financial Measures

Takeda's Core Financial Measures, particularly Core Revenue, Core Operating Profit, Core Net Profit for the Year attributable to owners of the Company and Core EPS, exclude revenue from divestments, amortization and impairment losses on intangible assets associated with products (includes in-process R&D) and other impacts unrelated to the underlying trends and business performance of Takeda's core operations, such as non-recurring items, purchase accounting effects and transaction related costs. **Core Revenue** represents revenue adjusted to exclude revenue items unrelated to the underlying trends and business performance of Takeda's core operations. **Core Operating Profit** represents operating profit adjusted to exclude other operating expenses and income, amortization and impairment losses on intangible assets associated with products (includes in-process R&D) and non-cash items or items unrelated to the underlying trends and business performance of Takeda's core operations. **Core EPS** represents net profit for the year attributable to owners of the Company, adjusted to exclude the impact of items excluded in the calculation of Core Operating Profit, and other non-operating items (e.g. amongst other items, fair value adjustments and the imputed financial charge related to contingent consideration) that are unusual, non-recurring in nature or unrelated to the underlying trends and business performance of Takeda's performance of Takeda's networks on going operations and the tax effect of each of the adjustments, divided by the average outstanding shares (excluding treasury shares) of the reporting periods presented.

Takeda presents its Core Financial Measures because Takeda believes that these measures are useful to understanding its business without the effect of items that Takeda considers to be unrelated to the underlying trends and business performance of its core operations, including items (i) which may vary significantly from year-to-year or may not occur in each year, or (ii) whose recognition Takeda believes is largely uncorrelated to trends in the underlying performance of our core business. Takeda believes that similar measures are frequently used by other companies in its industry, and that providing these measures helps investors evaluate Takeda's performance against not only its performance in prior years but on a similar basis as its competitors. Takeda also presents Core Financial Measures because these measures are used by Takeda for budgetary planning and compensation purposes (i.e., certain targets for the purposes of Takeda's Short-Term Incentive and Long-Term Incentive compensation programs, including incentive compensation of the CEO and CFO, are set in relation to the results of Takeda's Core Financial Measures).

Constant Exchange Rate ("CER") Change

Constant Exchange Rate Change eliminates the effect of foreign exchange rates from year-over-year comparisons by translating financial results in accordance with IFRS or Core (non-IFRS) financial measures for the current period using corresponding exchange rates in the same period of the previous fiscal year.

Takeda presents CER change because we believe that this measure is useful to investors to better understand the effect of exchange rates on our business, and to understand how our results of operations might have changed from year to year without the effect of fluctuations in exchange rates. These are the primary ways in which our management uses these measures to evaluate our results of operations. We also believe that this is a useful measure for investors as similar performance measures are frequently used by securities analysts, investors and other interested parties in the evaluation of the results of operations of other companies in our industry (many of whom similarly present measures that adjust for the effect of exchange rates).

The usefulness of this presentation has significant limitations including, but not limited to, that while CER change is calculated using the same exchange rates used to calculate financial results as presented under IFRS for the previous fiscal year, this does not necessarily mean that the transactions entered into during the relevant fiscal year could have been entered into or would have been recorded at the same exchange rates. Moreover, other companies in our industry using similarly titled measures may define and calculate those measures differently than we do, and therefore such measures may not be directly comparable. Accordingly, CER change should not be considered in isolation and is not, and should not be viewed as, a substitute for change in financial results as prepared and presented in accordance with IFRS. Starting from the quarter ended June 30, 2024, we ceased adjustments for CER change for the results of operations of subsidiaries in countries experiencing hyperinflation and for which IAS29, Financial Reporting in Hyperinflation Economies, is applied, because of the increased impacts of hyperinflation in the calculation of CER change using corresponding exchange rates in the same period of the previous fiscal year, effectively keeping CER change for these subsidiaries unchanged from those reported with IAS29.



Free Cash Flow and Adjusted Free Cash Flow

Takeda defines **Free Cash Flow** as cash flows from operating activities less acquisition of property, plant and equipment ("PP&E"). Takeda defines **Adjusted Free Cash Flow** as cash flows from operating activities, subtracting payments for acquisition of PP&E, intangible assets, investments (excluding debt investments classified as Level 1 in the fair value hierarchy), shares in associates, and businesses, net of cash and cash equivalents acquired, and other transactional payments deemed related or similar in substance thereto as well as adding proceeds from sales of PP&E, sales and redemption of investments (excluding debt investments classified as Level 1 in the fair value hierarchy), sales of shares in associates, and sales of businesses, net of cash and cash equivalents divested, and further adjusting for the movement of any other cash that is not available to Takeda's immediate or general business use.

Takeda presents Free Cash Flow and Adjusted Free Cash Flow because Takeda believes that these measures are useful to investors as similar measures of liquidity are frequently used by securities analysts, investors, and other interested parties in the evaluation of companies in our industry. Adjusted Free Cash Flow is also used by our management to evaluate our liquidity and our cash flows, particularly as they relate to our ability to meet our liquidity requirements and to support our capital allocation policies. Takeda also believes that Free Cash Flow and Adjusted Free Cash Flow are helpful to investors in understanding how our strategic acquisitions and divestitures of businesses contribute to our cash flows and liquidity.

The usefulness of Free Cash Flow and Adjusted Free Cash Flow to investors has significant limitations including, but not limited to, (i) they may not be comparable to similarly titled measures used by other companies, including those in our industry, (ii) they do not reflect the effect of our current and future contractual and other commitments requiring the use or allocation of capital and (iii) the addition of proceeds from sales and redemption of investments and the proceeds from sales of business, net of cash and cash equivalents divested do not represent cash received from our core ongoing operations. Free Cash Flow and Adjusted Free Cash Flow should not be considered in isolation and are not, and should not be viewed as, substitutes for cash flows from operating activities or any other measure of liquidity presented in accordance with IFRS. The most directly comparable measure under IFRS for Free Cash Flow and Adjusted Free Cash Flow is net cash from operating activities. Starting from the quarter ended June 30, 2024, we i) changed the title of Free Cash Flow as previously represented to "Adjusted Free Cash Flow" and ii) began reporting "Free Cash Flow" as cash flows from operating activities less acquisition of PP&E. This change is intended to enhance the comparability of our Free Cash Flow disclosures to those of our peers and to better describe the nature of these measures as presented by Takeda.

EBITDA and Adjusted EBITDA

Takeda defines **EBITDA** as consolidated net profit before income tax expenses, depreciation and amortization and net interest expense. Takeda defines **Adjusted EBITDA** as EBITDA further adjusted to exclude impairment losses, other operating income and expenses (excluding depreciation and amortization), finance income and expenses (excluding net interest expense), our share of loss from investments accounted for under the equity method and other items that management believes are unrelated to our core operations such as purchase accounting effects and transaction related costs.

Takeda presents EBITDA and Adjusted EBITDA because Takeda believes that these measures are useful to investors as they are frequently used by securities analysts, investors, and other interested parties in the evaluation of companies in our industry. Primarily, Adjusted EBITDA is used by Takeda for the purposes of monitoring its financial leverage. Takeda further believes that Adjusted EBITDA is helpful to investors in identifying trends in its business that could otherwise be obscured by certain items unrelated to ongoing operations because they are highly variable, difficult to predict, may substantially impact our results of operations and may limit the ability to evaluate our performance from one period to another on a consistent basis.

The usefulness of EBITDA and Adjusted EBITDA to investors has significant limitations including, but not limited to, (i) they may not be comparable to similarly titled measures used by other companies, including those in the pharmaceutical industry, (ii) they exclude financial information and events, such as the effects of an acquisition, or amortization of intangible assets, that some may consider important in evaluating Takeda's performance, value or prospects for the future, (iii) they exclude items or types of items that may continue to occur from period to period in the future and (iv) they may not include all items which investors may consider important to an understanding of our results of operations, or may not exclude all items which investors may not consider important for such understanding. EBITDA and Adjusted EBITDA should not be considered in isolation and are not, and should not be viewed as, substitutes for operating income, net profit for the year or any other measure of performance presented in accordance with IFRS. The most closely comparable measure presented in accordance with IFRS is net profit for the period.



Net Debt and Adjusted Net Debt

Takeda defines **Net Debt** as the book value of bonds and loans on consolidated statements of financial position adjusted only for cash and cash equivalents, and **Adjusted Net Debt** first by calculating the sum of the current and non-current portions of bonds and loans as shown on our consolidated statement of financial position, which is then adjusted to reflect (i) the use of prior 12-month average exchange rates for non-JPY debt outstanding at the beginning of the period and the use of relevant spot rates for new non-JPY debt incurred and existing non-JPY debt redeemed during the reporting period, which reflects the methodology our management uses to monitor our leverage, and (ii) the "equity credit" applied to Takeda's "hybrid" subordinated indebtedness by S&P Global Rating Japan in recognition of the equity-like features of those instruments pursuant to such agency's ratings methodology. To calculate Adjusted Net Debt, Takeda deducts from this figure cash and cash equivalents, excluding cash temporarily held by Takeda on behalf of third parties related to vaccine operations and to the trade receivables sales program, and debt investments classified as Level 1 in the fair value hierarchy being recorded as Other Financial Assets.

Takeda presents Net Debt and Adjusted Net Debt because Takeda believes that these measures are useful to investors in that our management uses it to monitor and evaluate our indebtedness, net of cash and cash equivalents, and, in conjunction with Adjusted EBITDA, to monitor our financial leverage (for the avoidance of doubt, Adjusted Net Debt and the ratio of Adjusted Net Debt to Adjusted EBITDA are not intended to be indicators of Takeda's liquidity). Takeda also believes that similar measures of indebtedness are frequently used by securities analysts, investors and other interested parties in the evaluation of companies in our industry. Particularly following the acquisition of Shire, investors, analysts and, in particular, ratings agencies, have closely monitored Takeda's leverage, as represented by the ratio of its Adjusted Net Debt to Adjusted EBITDA. In light of the weight given by ratings agencies in particular to this ratio, Takeda believes that such information is useful to investors to help understand not only Takeda's financial leverage, but also how ratings agencies evaluate the level of financial leverage in evaluating Takeda's quality of credit. Accordingly, as described below, Takeda includes an adjustment to its Adjusted Net Debt to reflect the "equity credit" afforded to certain of its subordinated indebtedness by ratings agencies (such indebtedness does not qualify for treatment as equity under IFRS).

The usefulness of Adjusted Net Debt to investors has significant limitations including, but not limited to, (i) it may not be comparable to similarly titled measures used by other companies, including those in the pharmaceutical industry, (ii) it does not reflect the amounts of interest payments to be paid on Takeda's indebtedness, (iii) it does not reflect any restrictions on Takeda's ability to prepay or redeem any of our indebtedness, (iv) it does not reflect any fees, costs or other expenses that Takeda may incur in converting cash equivalents to cash, in converting cash from one currency into another or in moving cash within our consolidated group, (v) it applies to gross debt an adjustment for average foreign exchange rates which, although consistent with Takeda's financing agreements, does not reflect the actual rates at which Takeda would be able to convert one currency into another and (vi) it reflects an equity credit despite the fact that Takeda's subordinated bonds are not eligible for equity treatment under IFRS, although Takeda believes this adjustment to be reasonable and useful to investors. Adjusted Net Debt should not be considered in isolation and is not, and should not be viewed as, a substitute for bonds and loans or any other measure of indebtedness presented in accordance with IFRS. The most directly comparable measures under IFRS for Net Debt is bonds and loans. Starting from the quarter ended June 30, 2024, we i) changed the title of Net Debt as previously represented to "Adjusted Net Debt" and ii) began reporting "Net Debt" as the book value of bonds and loans on consolidated statements of financial position adjusted only for cash and cash equivalents. This change is intended to enhance the comparability of our Net Debt disclosures to those of our peers and to better describe the nature of these measures as presented by Takeda.

U.S. Dollar Convenience Translations

In the Financial Appendix, certain amounts presented in Japanese yen have been translated to U.S. dollars solely for the convenience of the reader at an exchange rate of 1USD = 149.9 JPY, the Noon Buying Rate certified by the Federal Reserve Bank of New York on March 31, 2025. The rate and methodologies used for the convenience translations differ from the currency exchange rates and translation methodologies under IFRS used for the preparation of the condensed interim consolidated financial statements. The translation should not be construed as a representation that the Japanese yen amounts could be converted into U.S. dollars at this or any other rate.



FY2024 Reported Results with CER % Change

				(Million USD,			
(Billion JPY, except EPS)	FY2023	FY2024	AEI	R	CER	except EPS) FY2024 Convenience USD Translation	
			Amount of Change	% CHANGE	% CHANGE		
Revenue	4,263.8	4,581.6	317.8	7.5%	2.9%	30,564	
Cost of sales	(1,426.7)	(1,580.2)	(153.5)	(10.8)%	(6.5)%	(10,542)	
Gross profit	2,837.1	3,001.3	164.3	5.8%	1.1%	20,022	
Margin	66.5 %	65.5 %	6	(1.0) pp	(1.2) pp	65.5 %	
SG&A expenses	(1,053.8)	(1,104.8)	(50.9)	(4.8)%	(0.6)%	(7,370)	
R&D expenses	(729.9)	(730.2)	(0.3)	0.0%	4.5%	(4,871)	
Amortization of intangible assets associated with products	(521.5)	(548.2)	(26.7)	(5.1)%	0.3%	(3,657)	
Impairment losses on intangible assets associated with products ^{*1}	(130.6)	(95.0)	35.5	27.2%	28.7%	(634)	
Other operating income	19.4	26.2	6.8	35.3%	30.8%	175	
Other operating expenses	(206.5)	(206.7)	(0.2)	(0.1)%	3.6%	(1,379)	
Operating profit	214.1	342.6	128.5	60.0%	51.2%	2,285	
Margin	5.0 %	7.5 %	6	2.5 pp	2.4 рр	7.5 %	
Finance income	52.1	46.5	(5.5)	(10.6)%	(11.9)%	311	
Finance expenses	(219.8)	(210.1)	9.8	4.5%	7.2%	(1,401)	
Share of profit (loss) of investments accounted for using the equity method	6.5	(4.0)	(10.5)	_	_	(27)	
Profit before tax	52.8	175.1	122.3	231.7%	206.4%	1,168	
Income tax (expenses) benefit	91.4	(66.9)	(158.3)	_	_	(447)	
Net profit for the year	144.2	108.1	(36.1)	(25.0)%	(33.1)%	721	
Non-controlling interests	(0.1)	(0.2)	(0.1)	(65.7)%	(66.3)%	(1)	
Net profit attributable to owners of the Company	144.1	107.9	(36.1)	(25.1)%	(33.2)%	720	
Basic EPS (JPY or USD)	92.09	68.36	(23.73)	(25.8)%	(33.8)%	0.46	

*1 Includes in-process R&D

When comparing results to the previous fiscal year, the amount of change and percentage change based on Actual Exchange Rates are presented in "AER" (which is presented in accordance with IFRS) and percentage change based on Constant Exchange Rate (which is a non-IFRS measure) is presented in "CER". Please refer to *Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations,* for the definition of the "Constant Exchange Rate change".

% change versus the previous fiscal year is presented as positive when favorable to profits, and negative when unfavorable to profits.



FY2024 Q4 (Jan-Mar) Reported Results with CER % Change

				vs. PY			
(Billion JPY, except EPS)	FY2023 Q4 (Jan-Mar)	FY2024 Q4 (Jan-Mar)	AE	R	CER	except EPS) FY2024 Q4 (Jan-Mar)	
		(sur mar)	Amount of Change	% CHANGE	% CHANGE	Convenience USD Translation	
Revenue	1,050.9	1,053.4	2.5	0.2%	(2.0)%	7,027	
Cost of sales	(382.5)	(382.1)	0.4	0.1%	1.8%	(2,549)	
Gross profit	668.4	671.3	3.0	0.4%	(2.0)%	4,478	
Margin	63.6 %	63.7 %	6	0.1 pp	0.0 pp	63.7 %	
SG&A expenses	(285.2)	(295.9)	(10.6)	(3.7)%	(1.4)%	(1,974)	
R&D expenses	(195.9)	(216.0)	(20.2)	(10.3)%	(6.6)%	(1,441)	
Amortization of intangible assets associated with products	(133.8)	(136.5)	(2.7)	(2.0)%	1.9%	(911)	
Impairment losses on intangible assets associated with products ^{*1}	(11.3)	(66.5)	(55.3)	(489.6)%	(477.0)%	(444)	
Other operating income	9.3	10.4	1.1	11.9%	11.0%	70	
Other operating expenses	(61.6)	(41.8)	19.8	32.2%	32.5%	(279)	
Operating profit	(10.1)	(74.9)	(64.9)	(644.2)%	(602.8)%	(500)	
Margin	(1.0)%	(7.1)%	6	(6.2) pp	(5.9) pp	(7.1)%	
Finance income	6.6	18.7	12.1	183.0%	207.1%	125	
Finance expenses	(47.8)	(50.3)	(2.5)	(5.2)%	(5.1)%	(336)	
Share of profit (loss) of investments accounted for using the equity method	3.7	(0.8)	(4.5)	_	—	(5)	
Profit before tax	(47.5)	(107.3)	(59.8)	(125.8)%	(113.4)%	(716)	
Income tax (expenses) benefit	44.5	4.2	(40.3)	(90.6)%	(92.0)%	28	
Net profit for the period	(3.0)	(103.1)	(100.1)	(3,343.3)%	(3,167.9)%	(688)	
Non-controlling interests	(0.0)	(0.1)	(0.0)	(142.8)%	(147.3)%	(0)	
Net profit attributable to owners of the Company	(3.0)	(103.2)	(100.1)	(3,318.5)%	(3,144.5)%	(688)	
Basic EPS (JPY or USD)	(1.92)	(65.25)	(63.33)	(3,292.5)%	(3,119.9)%	(0.44)	

*1 Includes in-process R&D

When comparing results to the same period of the previous fiscal year, the amount of change and percentage change based on Actual Exchange Rates are presented in "AER" (which is presented in accordance with IFRS) and percentage change based on Constant Exchange Rate (which is a non-IFRS measure) is presented in "CER". Please refer to *Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations*, for the definition of the "Constant Exchange Rate change".

% change versus the same period of the previous fiscal year is presented as positive when favorable to profits, and negative when unfavorable to profits.



FY2024 Core Results with CER % Change

				(Million USD,			
(Billion JPY, except EPS)	FY2023	FY2024	A	R	CER	except EPS) FY2024	
			Amount of Change	% CHANGE	% CHANGE	Convenience USD Translation	
Revenue	4,263.8	4,579.8	316.1	7.4%	2.8%	30,553	
Cost of sales	(1,426.3)	(1,581.8)	(155.5)	(10.9)%	(6.6)%	(10,552)	
Gross profit	2,837.5	2,998.0	160.5	5.7%	0.9%	20,000	
Margin	66.5 %	65.5 %	6	(1.1) pp	(1.2) pp	65.5 %	
SG&A expenses	(1,053.0)	(1,105.0)	(52.1)	(4.9)%	(0.7)%	(7,372)	
R&D expenses	(729.6)	(730.4)	(0.7)	(0.1)%	4.4%	(4,872)	
Operating profit	1,054.9	1,162.6	107.8	10.2%	4.9%	7,756	
Margin	24.7 %	25.4 %	6	0.6 pp	0.5 pp	25.4 %	
Finance income	51.5	34.3	(17.2)	(33.4)%	(34.5)%	229	
Finance expenses	(193.5)	(175.0)	18.5	9.6%	12.5%	(1,167)	
Share of profit (loss) of investments accounted for using the equity method	5.9	1.1	(4.8)	(81.2)%	(82.2)%	7	
Profit before tax	918.8	1,023.1	104.3	11.3%	5.8%	6,825	
Income tax (expenses) benefit	(161.9)	(247.3)	(85.4)	(52.7)%	(48.7)%	(1,649)	
Net profit for the year	756.9	775.8	18.9	2.5%	(3.4)%	5,176	
Non-controlling interests	(0.1)	(0.2)	(0.1)	(65.7)%	(66.3)%	(1)	
Net profit attributable to owners of the Company	756.8	775.6	18.8	2.5%	(3.4)%	5,174	
Basic EPS (JPY or USD)	484	491	7	1.5%	(4.3)%	3.28	

When comparing results to the previous fiscal year, the amount of change and percentage change based on Actual Exchange Rates are presented in "AER" (which is presented in accordance with IFRS) and percentage change based on Actual Exchange Rates are presented in "AER" (which is presented in accordance with IFRS) and percentage change based on Constant Exchange Rates are presented in "AER" (which is a non-IFRS measure) is presented in "CER". Please refer to *Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations,* for the definition of the "Constant Exchange Rate change".

% change versus the previous fiscal year is presented as positive when favorable to profits, and negative when unfavorable to profits.



FY2024 Q4 (Jan-Mar) Core Results with CER % Change

				(Million USD,			
(Billion JPY, except EPS)	FY2023 Q4 (Jan-Mar)	FY2024 Q4 (Jan-Mar)	AER		CER	 except EPS) FY2024 Q4 (Jan-Mar) 	
	(Jun Mary	(can mary	Amount of Change	% CHANGE	% CHANGE	Convenience USD Translation	
Revenue	1,050.9	1,051.7	0.8	0.1%	(2.1)%	7,016	
Cost of sales	(382.0)	(383.5)	(1.4)	(0.4)%	1.4%	(2,558)	
Gross profit	668.8	668.2	(0.6)	(0.1)%	(2.6)%	4,458	
Margin	63.6 %	63.5 %		(0.1) pp	(0.3) pp	63.5 %	
SG&A expenses	(283.9)	(295.8)	(11.9)	(4.2)%	(1.9)%	(1,974)	
R&D expenses	(195.6)	(216.0)	(20.4)	(10.4)%	(6.8)%	(1,441)	
Operating profit	189.3	156.4	(33.0)	(17.4)%	(18.9)%	1,043	
Margin	18.0 %	14.9 %		(3.1) pp	(3.1) pp	14.9 %	
Finance income	6.5	12.9	6.3	96.9%	121.1%	86	
Finance expenses	(41.2)	(47.4)	(6.2)	(15.0)%	(14.9)%	(316)	
Share of profit (loss) of investments accounted for using the equity method	1.6	(0.4)	(2.0)	_	_	(3)	
Profit before tax	156.2	121.4	(34.8)	(22.3)%	(23.0)%	810	
Income tax (expenses) benefit	(43.0)	(44.7)	(1.7)	(4.0)%	(5.1)%	(298)	
Net profit for the period	113.2	76.8	(36.5)	(32.2)%	(33.6)%	512	
Non-controlling interests	(0.0)	(0.1)	(0.0)	(142.8)%	(147.3)%	(0)	
Net profit attributable to owners of the Company	113.2	76.7	(36.5)	(32.3)%	(33.7)%	512	
Basic EPS (JPY or USD)	72	49	(24)	(32.8)%	(34.2)%	0.32	

When comparing results to the same period of the previous fiscal year, the amount of change and percentage change based on Actual Exchange Rates are presented in "AER" (which is presented in accordance with IFRS) and percentage change based on Constant Exchange Rate (which is a non-IFRS measure) is presented in "CER". Please refer to *Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations*, for the definition of the "Constant Exchange Rate change".

% change versus the same period of the previous fiscal year is presented as positive when favorable to profits, and negative when unfavorable to profits.



FY2024 Reconciliation from Reported to Core

(Billion JPY, except EPS and number of shares)	REPORTED	Amortization of intangible assets	Impairment of intangible assets	Teva JV related adjustment	Other operating income/ expenses	Others	CORE
Revenue	4,581.6			(1.7)			4,579.8
Cost of sales	(1,580.2)					(1.6)	(1,581.8)
Gross profit	3,001.3			(1.7)		(1.6)	2,998.0
SG&A expenses	(1,104.8)					(0.3)	(1,105.0)
R&D expenses	(730.2)					(0.1)	(730.4)
Amortization of intangible assets associated with products	(548.2)	548.2					_
Impairment losses on intangible assets associated with products ^{*1}	(95.0)		95.0				_
Other operating income	26.2			(3.8)	(22.4)		_
Other operating expenses	(206.7)				206.7		_
Operating profit	342.6	548.2	95.0	(5.6)	184.3	(2.0)	1,162.6
Margin	7.5 %						25.4 %
Finance income and (expenses), net	(163.5)			18.9		4.0	(140.7)
Share of profit (loss) of investments accounted for using the equity method	(4.0)					5.1	1.1
Profit before tax	175.1	548.2	95.0	13.3	184.3	7.1	1,023.1
Income tax (expenses) benefit	(66.9)	(114.9)	(23.4)	(4.1)	(45.1)	7.3	(247.3)
Non-controlling interests	(0.2)						(0.2)
Net profit attributable to owners of the Company	107.9	433.3	71.6	9.3	139.2	14.3	775.6
Basic EPS (JPY)	68						491
Number of shares (millions)	1,579						1,579



FY2024 Q4 (Jan-Mar) Reconciliation from Reported to Core

			REPORT	ED TO CORE ADJUS	TMENTS		
(Billion JPY, except EPS and number of shares)	REPORTED	Amortization of intangible assets	Impairment of intangible assets	Teva JV related adjustment	Other operating income/ expenses	Others	CORE
Revenue	1,053.4			(1.7)			1,051.7
Cost of sales	(382.1)					(1.4)	(383.5)
Gross profit	671.3			(1.7)		(1.4)	668.2
SG&A expenses	(295.9)					0.0	(295.8)
R&D expenses	(216.0)					(0.0)	(216.0)
Amortization of intangible assets associated with products	(136.5)	136.5					_
Impairment losses on intangible assets associated with products ^{*1}	(66.5)		66.5				_
Other operating income	10.4			(3.8)	(6.6)		_
Other operating expenses	(41.8)				41.8		
Operating profit	(74.9)	136.5	66.5	(5.6)	35.1	(1.4)	156.4
Margin	(7.1)%						14.9 %
Finance income and (expenses), net	(31.6)			(0.5)		(2.5)	(34.5)
Share of profit (loss) of investments accounted for using the equity method	(0.8)					0.4	(0.4)
Profit before tax	(107.3)	136.5	66.5	(6.0)	35.1	(3.4)	121.4
Income tax (expenses) benefit	4.2	(28.8)	(15.2)	1.8	(8.6)	1.9	(44.7)
Non-controlling interests	(0.1)						(0.1)
Net profit attributable to owners of the Company	(103.2)	107.8	51.3	(4.2)	26.5	(1.5)	76.7
Basic EPS (JPY)	(65)						49
Number of shares (millions)	1,581						1,581



FY2023 Reconciliation from Reported to Core

(Billion JPY, except EPS and number of shares)	REPORTED	Amortization of intangible assets	Impairment of intangible assets	Other operating income/ expenses	Others	CORE
Revenue	4,263.8					4,263.8
Cost of sales	(1,426.7)				0.4	(1,426.3)
Gross profit	2,837.1				0.4	2,837.5
SG&A expenses	(1,053.8)				0.9	(1,053.0)
R&D expenses	(729.9)				0.3	(729.6)
Amortization of intangible assets associated with products	(521.5)	521.5				_
Impairment losses on intangible assets associated with products ^{*1}	(130.6)		130.6			_
Other operating income	19.4			(19.4)		_
Other operating expenses	(206.5)			206.5		
Operating profit	214.1	521.5	130.6	187.1	1.5	1,054.9
Margin	5.0 %					24.7 %
Finance income and (expenses), net	(167.8)				25.8	(142.0)
Share of profit (loss) of investments accounted for using the equity method	6.5				(0.5)	5.9
Profit before tax	52.8	521.5	130.6	187.1	26.8	918.8
Income tax (expenses) benefit	91.4	(108.7)	(28.6)	(43.1)	(73.0)	(161.9)
Non-controlling interests	(0.1)					(0.1)
Net profit attributable to owners of the Company	144.1	412.8	102.0	144.1	(46.2)	756.8
Basic EPS (JPY)	92					484
Number of shares (millions)	1,564					1,564



FY2023 Q4 (Jan-Mar) Reconciliation from Reported to Core

			REPORTED TO CO	RE ADJUSTMENTS		
(Billion JPY, except EPS and number of shares)	REPORTED	Amortization of intangible assets	Impairment of intangible assets	Other operating income/ expenses	Others	CORE
Revenue	1,050.9					1,050.9
Cost of sales	(382.5)				0.5	(382.0)
Gross profit	668.4				0.5	668.8
SG&A expenses	(285.2)				1.3	(283.9)
R&D expenses	(195.9)				0.3	(195.6)
Amortization of intangible assets associated with products	(133.8)	133.8				_
Impairment losses on intangible assets associated with products ^{*1}	(11.3)		11.3			_
Other operating income	8.6			(8.6)		_
Other operating expenses	(60.8)			60.8		_
Operating profit	(10.1)	133.8	11.3	52.2	2.0	189.3
Margin	(1.0)%					18.0 %
Finance income and (expenses), net	(41.2)				6.5	(34.7)
Share of profit (loss) of investments accounted for using the equity method	3.7				(2.2)	1.6
Profit before tax	(47.5)	133.8	11.3	52.2	6.4	156.2
Income tax (expenses) benefit	44.5	(26.2)	(2.2)	(11.3)	(47.9)	(43.0)
Non-controlling interests	(0.0)					(0.0)
Net profit attributable to owners of the Company	(3.0)	107.7	9.1	40.9	(41.5)	113.2
Basic EPS (JPY)	(2)					72
Number of shares (millions)	1,569					1,569



FY2024 Adjusted Free Cash Flow

(Billion JPY)	FY2023	FY2024	vs.	РҮ	(Million USD) FY2024 Convenience USD Translation
Net profit	144.2	108.1	(36.1)	(25.0)%	721
Depreciation, amortization and impairment losses	878.0	867.9	(10.1)		5,790
Decrease (increase) in trade working capital	(110.5)	(101.0)	9.5		(674)
Income taxes paid	(219.9)	(170.6)	49.4		(1,138)
Tax refunds and interest on tax refunds received	17.9	20.2	2.3		135
Other	6.7	332.6	325.9		2,219
Net cash from operating activities (Operating Cash Flow)	716.3	1,057.2	340.8	47.6 %	7,053
Acquisition of PP&E	(175.4)	(200.8)	(25.4)		(1,340)
Free Cash Flow ^{*1}	540.9	856.4	315.5	58.3 %	5,713
Adjustment for cash temporarily held by Takeda on behalf of third parties ^{*2}	18.0	2.1	(15.9)		14
Proceeds from sales of PP&E	8.6	0.1	(8.5)		1
Acquisition of intangible assets ^{*3}	(305.3)	(147.0)	158.3		(981)
Acquisition of option to license	_	(31.8)	(31.8)		(212)
Acquisition of investments ^{*4}	(6.8)	(17.4)	(10.7)		(116)
Proceeds from sales and redemption of investments	8.0	29.4	21.4		196
Acquisition of shares in associates	—	(1.0)	(1.0)		(7)
Proceeds from sales of shares in associates	—	57.7	57.7		385
Proceeds from sales of business, net of cash and cash equivalents divested	20.0	20.6	0.6		137
Adjusted Free Cash Flow ^{*1}	283.4	769.0	485.5	171.3 %	5,130

*1 Please refer to Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations for additional information on change in the titles and definitions of Free Cash Flow and Adjusted Free Cash Flow from FY2024.

*2 Adjustment for cash temporarily held by Takeda on behalf of third parties refers to changes in cash balances that are temporarily held by Takeda on behalf of third parties related to vaccine operations and the trade receivables sales program, which are not available to Takeda's immediate or general business use.

*3 Proceeds from sale of intangible assets are separately adjusted as they are recorded within operating cash flows, except certain immaterial transactions.

*4 Acquisition of JPY 80.1 billion debt investments classified as Level 1 in the fair value hierarchy is excluded for the fiscal year ended March 31, 2025.



FY2024 Adjusted Net Debt to Adjusted EBITDA

NET DEBT/ADJUSTED EBITDA RATIO

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

(Billion JPY)FY2024Book value of bonds and loans on consolidated statements of financial position(4,515.3)		(Billion JPY)	FY2023	FY2024	vs. P	Υ
		Net cash from operating activities (Operating Cash Flow)	716.3	1,057.2	340.8	47.6 %
		Acquisition of PP&E	(175.4)	(200.8)		
Cash & cash equivalents	385.1	Proceeds from sales of PP&E	8.6	0.1		
Net Debt ^{*1}	(4,130.2)	Acquisition of intangible assets	(305.3)	(147.0)		
Application of equity credit ^{*2}	250.0	Acquisition of option to license	_	(31.8)		
FX adjustment ^{*3}	(68.9)	Acquisition of investments		(97.5)		
Cash temporarily held by Takeda on behalf of third parties ^{*4}	(105.8)	Proceeds from sales and redemption of investments	8.0	29.4		
Level 1 debt investments ^{*4}	79.3	Acquisition of shares in associates	_	(1.0)		
Adjusted Net Debt ^{*1}	(3,975.5)	Proceeds from sales of shares in associates	_	57.7		
		Proceeds from sales of business, net of cash and cash equivalents divested	20.0	20.6		
Adjusted EBITDA	1,441.0	Payments for the settlement of forward exchange contracts designated as net investment hedges	(33.3)	(13.8)		
Adjusted Net Debt/Adjusted EBITDA ratio	2.8x	Net increase (decrease) in short-term loans and commercial papers	277.0	27.5		
		Proceeds from long-term loans	100.0	90.0		
Book value of bonds and loans on consolidated statements of		Repayment of long-term loans	(100.4)	(587.2)		
financial position	(4,515.3)	Proceeds from issuance of bonds	_	934.5		
Application of equity credit ^{*2}	250.0	Repayment of bonds	(220.5)	(733.8)		
FX adjustment ^{*3}	(68.9)	Proceeds from the settlement of cross currency interest rate swaps related to bonds	60.1	46.0		
Adjusted Gross Debt	(4,334.2)	and loans	60.1	46.9		
	-	Acquisition of treasury shares	(2.3)	(51.9)		
		Interest paid	(100.4)	(113.0)		
		Dividends paid	(287.2)	(302.5)		
		Others	(60.3)	(44.6)		
		Net increase (decrease) in cash and cash equivalents	(101.9)	(61.3)	40.6	39.9 %

*1 Please refer to Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations for additional information on change in the titles and definitions of Net Debt and Adjusted Net Debt from FY2024.

*2 Application of equity credit includes JPY 250.0 billion reduction in debt due to a 50% equity credit applied to JPY 500.0 billion principal amount of our hybrid (subordinated) bonds and loans by S&P Global Rating Japan, given that those instruments qualify for certain equity credit for leverage purposes.

*3 FX adjustment refers to change from month-end rate to average rate used for non-JPY debt calculation outstanding at the beginning of the period to match with adjusted EBITDA (which is calculated based on average rates). New non-JPY debt incurred and existing non-JPY debt redeemed during the reporting period are translated to JPY at relevant spot rates as of the relevant date.

*4 Adjustments related to cash temporarily held by Takeda on behalf of third parties related to vaccine operations and to the trade receivables sales program, which is not available to Takeda's immediate or general business use, and debt investments classified as Level 1 in the fair value hierarchy being recorded as Other Financial Assets.



FY2023 Adjusted Net Debt to Adjusted EBITDA

NET	DEBT	/ADJL	JSTED	EBITDA	RATIO
-----	------	-------	-------	---------------	-------

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

(Billion JPY)	FY2023	(Billion JPY)	FY2022	FY2023	vs. PY	
Book value of bonds and loans on consolidated statements of	(4,843.8)	Net cash from operating activities (Operating Cash Flow)	977.2	716.3	(260.8)	(26.7)%
financial position	(4,045.0)	Acquisition of PP&E	(140.7)	(175.4)		
Cash & cash equivalents	457.8	Proceeds from sales of PP&E	1.0	8.6		
Net Debt ^{*1}	(4,386.0)	Acquisition of intangible assets	(493.0)	(305.3)		
Application of equity credit ^{*2}	250.0	Acquisition of investments	(10.2)	(6.8)		
FX adjustment ^{*3}	152.5	Proceeds from sales and redemption of investments	22.3	8.0		
Cash temporarily held by Takeda on behalf of third parties ^{*4}	(107.8)	Proceeds from sales of business, net of cash and cash equivalents divested	8.0	20.0		
Level 1 debt investments ^{*4}	_	Net increase in short-term loans and commercial papers	40.0	277.0		
Adjusted Net Debt ^{*1}	(4,091.3)	Proceeds from long-term loans	75.0	100.0		
		Repayment of long-term loans	(75.2)	(100.4)		
Adjusted EBITDA	1,319.9	Repayment of bonds	(281.5)	(220.5)		
		Proceeds from the settlement of cross currency interest rate swaps related to bonds	_	60.1		
Adjusted Net Debt/Adjusted EBITDA ratio	3.1x	Purchase of treasury shares	(26.9)	(2.3)		
		Interest paid	(108.6)	(100.4)		
Book value of bonds and loans on consolidated statements of	(4 942 9)	Dividends paid	(279.4)	(287.2)		
financial position	(4,843.8)	Others	(47.0)	(93.6)		
Application of equity credit ^{*2}	250.0	Net increase (decrease) in cash and cash equivalents	(339.1)	(101.9)	237.2	69.9 %
FX adjustment ^{*3}	152.5					
Adjusted Gross Debt	(4,441.2)					

*1 The FY2023 presentation included herein has been adjusted for new definitions applied starting from the quarter ended June 30, 2024; please refer to *Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations* for additional information on change in the titles and definitions of Net Debt and Adjusted Net Debt from FY2024.

*2 Application of equity credit includes JPY 250.0 billion reduction in debt due to a 50% equity credit applied to JPY 500.0 billion principal amount of our hybrid (subordinated) bonds and loans by S&P Global Rating Japan, given that those instruments qualify for certain equity credit for leverage purposes.

*3 FX adjustment refers to change from month-end rate to average rate used for non-JPY debt calculation outstanding at the beginning of the period to match with adjusted EBITDA (which is calculated based on average rates). New non-JPY debt incurred and existing non-JPY debt redeemed during the reporting period are translated to JPY at relevant spot rates as of the relevant date.

*4 Adjustments related to cash temporarily held by Takeda on behalf of third parties related to vaccine operations and to the trade receivables sales program, which is not available to Takeda's immediate or general business use, and debt investments classified as Level 1 in the fair value hierarchy being recorded as Other Financial Assets.



FY2024 Net Profit to Adjusted EBITDA Bridge

(Billion JPY)	FY2023	FY2024	vs. PY		
Net profit	144.2	108.1	(36.1)	(25.0)%	
Income tax expenses (benefit)	(91.4)	66.9			
Depreciation and amortization	728.0	761.4			
Interest expense, net	108.2	117.7			
EBITDA	889.0	1,054.2	165.1	18.6 %	
Impairment losses	150.0	106.5			
Other operating expense (income), net, excluding depreciation and amortization and other miscellaneous expenses (non-cash item)	162.2	163.2			
Finance expense (income), net, excluding interest expense, net	59.5	45.8			
Share of loss (profit) on investments accounted for under the equity method	(6.5)	4.0			
Other adjustments:	69.9	67.4			
Teva JV related adjustment	_	(1.7)			
Other costs ^{*1}	69.9	69.2			
EBITDA from divested products ^{*2}	(4.2)	(0.2)			
Adjusted EBITDA	1,319.9	1,441.0	121.1	9.2 %	

*1 Includes adjustments for non-cash equity-based compensation expense and other one time non-cash expense.

*2 Represents adjustments for EBITDA from divested products which are removed as part of Adjusted EBITDA.



FY2024 CAPEX, Depreciation and Amortization and Impairment Losses

(Billion JPY)	FY2023	FY2024	vs.	vs. PY	
Capital expenditures ^{*1}	480.7	347.8	(132.9)	(27.6)%	270.0 - 320.0
Tangible assets	175.4	200.8	25.4	14.5 %	
Intangible assets	305.3	147.0	(158.3)	(51.8)%	
Depreciation and amortization	728.0	761.4	33.4	4.6 %	716.0
Depreciation of tangible assets ^{*2} (A)	174.1	173.8	(0.3)	(0.1)%	
Amortization of intangible assets (B)	553.9	587.6	33.7	6.1 %	
Of which Amortization associated with products (C)	521.5	548.2	26.7	5.1 %	500.0
Of which Amortization excluding intangible assets associated with products (D)	32.4	39.4	7.0	21.6 %	
Depreciation and amortization (excluding intangible assets associated with products) (A)+(D)	206.5	213.2	6.7	3.3 %	216.0
Impairment losses	150.0	106.5	(43.5)	(29.0)%	
Impairment losses on intangible assets associated with products ^{*3}	130.6	95.0	(35.5)	(27.2)%	50.0
Amortization and impairment losses on intangible assets associated with products	652.1	643.2	(8.9)	(1.4)%	550.0

*1 Cash flow base

*2 Includes depreciation of investment properties



FY2024 Actual vs. Forecast (Jan. 2025)

(B	(Y9L N	FY2024 Forecast (January 30, 2025)	FY2024 Actual	vs. Fo	orecast	Variances
	Revenue	4,590.0	4,581.6	(8.4)	(0.2)%	Mainly FX headwind
	Cost of sales	(1,585.0)	(1,580.2)	4.8	0.3%	Mainly FX benefit
	Gross Profit	3,005.0	3,001.3	(3.7)	(0.1)%	
	SG&A expenses	(1,115.0)	(1,104.8)	10.2	0.9%	Mainly FX benefit
	R&D expenses	(740.0)	(730.2)	9.8	1.3%	Mainly FX benefit
~	Amortization of intangible assets associated with products	(550.0)	(548.2)	1.8	0.3%	
REPORTED	Impairment losses on intangible assets associated with $\operatorname{products}^{*1}$	(50.0)	(95.0)	(45.0)	(90.1)%	Loss due to termination of TAK-186 and TAK-280 acquired through Maverick Therapeutics Inc. (27.8 B) and others
REPO	Other operating income	19.0	26.2	7.2	38.0%	Revaluation of contingent consideration and deferred income recognized as a result of the Teva JV divestiture
	Other operating expenses	(225.0)	(206.7)	18.3	8.1%	Lower pre-launch inventory
	Operating profit	344.0	342.6	(1.4)	(0.4)%	
	Finance income (expenses), net	(178.0)	(163.5)	14.5	8.1%	FX gain and derivative gain associated with prepaid syndicated loan
	Profit before tax	162.0	175.1	13.1	8.1%	
	Net profit attributable to owners of the Company	118.0	107.9	(10.1)	(8.5)%	Increase in US international tax provision (e.g., BEAT) and lower R&D tax credits
	Basic EPS (yen)	75	68	(6)	(8.5)%	
	Core Revenue ^{*2}	4,590.0	4,579.8	(10.2)	(0.2)%	Mainly FX headwind
	Core Operating Profit ^{*2}	1,150.0	1,162.6	12.6	1.1%	Mainly FX benefit
	Core EPS (yen) ^{*2}	507	491	(15)	(3.0)%	
	Adjusted Free Cash Flow ^{*2}	550.0 to 650.0	769.0			Higher Core OP, lower cash tax, restructuring cost, capex, and working capital
	CAPEX (cash flow base)	(380.0) to (420.0)	(347.8)			Lower than projected business development spend
	Depreciation and amortization (excl. intangible assets associated with products)	(218.0)	(213.2)	4.8	2.2%	
	Cash tax rate on Adjusted EBITDA (excl. divestitures) ^{*2}	Low teen %	Approx.10%			
	USD/JPY	153	152	(0)	(0.3)%	
	EUR/JPY	165	163	(2)	(0.9)%	

*1 Includes in-process R&D.

*2 Please refer to Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations, for the definition of Non-IFRS Measures and FY2025 Full Year Reconciliation from Reported Operating Profit to Core Operating Profit Forecast.



FY2025 Full Year Detailed Forecast

(BI	(YAF N	FY2024 Actual	FY2025 Forecast (May 8, 2025)	vs	. PY	Variances
	Revenue	4,581.6	4,530.0	(51.6)	(1.1)%	LOE impact (mainly VYVANSE), pricing and FX headwinds, partially offset by Growth & Launch Products
	Cost of sales	(1,580.2)	(1,540.0)	40.2	2.5%	
	Gross Profit	3,001.3	2,990.0	(11.3)	(0.4)%	Less impact from implementation of accounting process to recognize accumulated FX impact of inventories
	SG&A expenses	(1,104.8)	(1,100.0)	4.8	0.4%	Savings from the Efficiency Program and FX benefits partially offset by investments in DD&T and new launches
	R&D expenses	(730.2)	(750.0)	(19.8)	(2.7)%	Ramp-up of trial costs offset by the Efficiency Program and FX benefits
Ö	Amortization of intangible assets associated with products	(548.2)	(500.0)	48.2	8.8%	Conclusion of amortization of several products, including VYVANSE (in January FY25)
RT	Impairment losses on intangible assets associated with products ^{*1}	(95.0)	(50.0)	45.0	47.4%	
REPORTED	Other operating income	26.2	10.0	(16.2)	(61.9)%	Reduction of divestiture gains (FY24 TACHOSIL manufacturing site) and others
R	Other operating expenses	(206.7)	(125.0)	81.7	39.5%	Primarily reflects lower restructuring expenses projected in FY25 (FY24 actual: 128.1 B vs. FY25 forecast: 48.0 B)
	Operating profit	342.6	475.0	132.4	38.7%	
	Finance income (expenses), net	(163.5)	(167.0)	(3.5)	(2.1)%	
	Profit before tax	175.1	307.0	131.9	75.3%	
	Net profit attributable to owners of the Company	107.9	228.0	120.1	111.3%	Mainly driven by increase of profit before tax partially offset by lower derecognition of tax loss carry forward
	Basic EPS (yen)	68	145	76	111.8%	
	Core Revenue ^{*2}	4,579.8	4,530.0	(49.8)	(1.1)%	LOE impact (mainly VYVANSE), pricing and FX headwinds, partially offset by Growth & Launch Products
	Core Operating Profit ^{*2}	1,162.6	1,140.0	(22.6)	(1.9)%	Maily due to FX headwinds
	Core EPS (yen) ^{*2}	491	485	(6)	(1.2)%	
	Adjusted Free Cash Flow ^{*2}	769.0	750.0 to 850.0			While Core OP is flat FY 24 vs. FY 25, we expect higher FCF in FY 25 mainly due to lower restructuring spend in FY 25
	CAPEX (cash flow base)	(347.8)	(270.0) to (320.0)			
	Depreciation and amortization (excl. intangible assets associated with products)	(213.2)	(216.0)	(2.8)	(1.3)%	
	Cash tax rate on Adjusted EBITDA (excl. divestitures) ^{*2}	Approx.10%	Mid teen%			
	USD/JPY	152	150	(2)	(1.6)%	
	EUR/JPY	163	160	(3)	(2.1)%	

*1 Includes in-process R&D.

*2 Please refer to Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations, for the definition of Non-IFRS Measures and FY2025 Full Year Reconciliation from Reported Operating Profit to Core Operating Profit Forecast.



FY2025 Full Year Reconciliation from Reported Operating Profit to Core Operating Profit Forecast

		REPOR	TED TO CORE ADJUST	MENTS		
(Billion JPY)	REPORTED	Amortization of intangible assets	Impairment of intangible assets	Other operating income (expenses)	CORE	
Revenue	4,530.0				4,530.0	
Cost of sales	(1,540.0)					
Gross Profit	2,990.0				(3,390.0)	
SG&A expenses	(1,100.0)				(3,390.0)	
R&D expenses	(750.0)					
Amortization of intangible assets associated with products	(500.0)	500.0			_	
Impairment losses on intangible assets associated with products ^{*1}	(50.0)		50.0		_	
Other operating income	10.0			(10.0)		
Other operating expenses	(125.0)			125.0	_	
Operating profit	475.0	500.0	50.0	115.0	1,140.0	



FY2025 Full Year FX Rates Assumptions and Currency Sensitivity vs. Forecast

Average Exchange Rates vs. JPY				Impact of depreciation of yen from April 2025 to March 2026 (100 million JPY)				
	FY2023 Actual (Apr-Mar)	FY2024 Actual (Apr-Mar)	FY2025 Full Year Assumption (Apr-Mar)		Revenue (IFRS)	Operating Profit (IFRS)	Net Profit (IFRS)	Core Operating Profit (non-IFRS)
USD	144	152	150	1% depreciation	234.3	8.3	(1.1)	52.5
				1 yen depreciation	156.2	5.5	(0.7)	35.0
EUR	156	163	160	1% depreciation	65.6	(28.2)	(25.0)	(17.1)
				1 yen depreciation	41.0	(17.6)	(15.7)	(10.7)
RUB	1.6	1.6	1.7	1% depreciation	5.6	3.3	2.5	3.8
CNY	20.1	21.1	20.5		19.5	11.8	8.9	11.9
BRL	29.1	27.4	25.9		12.9	9.7	6.4	9.8

Takeda Investor Relations: takeda.ir.contact@takeda.com



Better Health, Brighter Future

© 2025 Takeda Pharmaceutical Company Limited. All rights reserved.